6,678 trials
Papulopustular Rosacea
Primary: Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) at Week 2 (LOCF: Last Observation Carried Forward) — -10.5; -9.4…
Nausea and Vomiting, Postoperative
Primary: Incidence of Nausea — 46; 54 percentage of participants
HIV
Primary: Maximum Observed Plasma Concentration (Cmax) and Trough Observed Plasma Concentration (Ctrough) for Atazanavir and Ritonavir — 3512; 4131; 3322; 496 ng/mL
Alcohol Consumption
Primary: Evidence of Attempts to Drive After Drinking — -1.29; -0.30 percent of days
Pulmonary Hypertension
Primary: Observed the Change of Pulmonary Artery Systolic Pressure (PASP) Measured by Millimeters of Mercury (mm hg) Within Certain Time Periods. This is Per Sequence and Not a…
HIV Infections
Primary: Mean Change From Baseline CD4+ Cell Count — 8.62; 2.68; 8.68; 21.87 Cells/microlitre — p=<0.01
Pulmonary Arterial Hypertension
Primary: Safety and Tolerability of ACT-385781A and Flolan in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) - Number of Patients With…
Pulmonary Arterial Hypertension
Primary: Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 2 ng/kg/Min — 98.0; 83.1 (pg/ml)/(ng/kg/min)
Muscle Spasticity
Primary: Physician Assessment of Success, as Determined by Percentage of Patients Who Achieve Their Principal Active Functional Goal at Week 24 — 40.9; 33.3 Percentage of Patients
Tinea Versicolor
Primary: The Effect of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor — 7; 4 participants
Psoriasis · Melanoma · Non-melanoma Skin Cancer
Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants
Flank Pain · Urinary Bladder, Overactive
Primary: Change in Post-ureteroscopy Stent-induced Pain — 4.61; 3.11 units on a scale
Hepatitis B
Primary: Number of Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentration Equal to or Above (≥) 100 Milli-International Units Per Milliliter (mIU/mL) — 251 Participants
Critically Ill Renal Failure Requiring CVVHD and Oseltamivir · Critically Ill Requiring ECMO and Oseltamivir
Primary: Continuous Venovenous Hemodialysis (CVVHD)Oseltamivir Carboxylate Transmembrane Clearance — 52.2; 43.3 mL/min
Obesity · Hypertension · Hyperglycemia
Primary: Insulin Sensitivity Utilizing the Euglycemic Hyperinsulinemic Clamp — 5.3; 2.8 mg/kg/min